Jump to content

Draft:Bart Vanhaesebroeck

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by GBH12 (talk | contribs) at 14:55, 8 July 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Bart Vanhaesebroeck

Bart Vanhaesebroeck FRS is a Belgian-UK scientist based at University College London. Vanhaesebroeck is Professor of Cell Signalling at the UCL Cancer Institute.

Career

Following a PhD (1990) with Johan Grooten and Walter Fiers at the laboratory of Molecular Biology in Ghent (Belgium), Vanhaesebroeck performed postdoctoral studies with Michael Waterfield FRS at the Ludwig Institute for Cancer Research (London Branch) where he set up his independent research group in 1998. He became Professor at University College London (2005) and Associate Member of the Ludwig Institute for Cancer Research (2006). In 2007, he moved to Barts Cancer Institute at Queen Mary University of London to set up the Centre for Cell Signalling. In 2014, he became Professor of Cell Signalling at the UCL Cancer Institute.

Research interests

Vanhaesebroeck's research team has made fundamental discoveries in the field of cell signalling by lipid second messengers, work which has led to approved medicines for leukemia.

Vanhaesebroeck’s contributions include uncovering the functions of PI 3-kinase (PI3K) family members[1] and the identification of PI3Kd[2], the main PI3K in white blood cells, in which it controls immune functions[3]. His work has underpinned the generation of PI3Kd inhibitors that are currently used in the treatment of haematological malignancies and are being trialled in cancer immunotherapy[4] [5] of solid tumours. His team’s development of small molecule PI3K activators has opened new avenues for kinase drug development and their therapeutic applications.

Awards and honours

Vanhaesebroeck was elected as a Member of the European Molecular Biology Organisation (2012) and a Fellow of the Royal Society of Biology (2011), the Academy of Medical Sciences (2016) and the Royal Society (2024).

References

  1. ^ Vanhaesebroeck, Bart; Stephens, L; Hawkins, P (2012). "PI3K signalling: the path to discovery and understanding". Nat Rev Mol Cell Biol. 13: 195-203. doi:10.1038/nrm3290.
  2. ^ Vanhaesebroeck, B; Welham, M.J; Kotani, K; Stein, R; Warne, P.H; Zvelebil, M.J; Higashi, K; Volinia, S; Downward, J; Waterfield, M.D (1997). "P110delta, a novel phosphoinositide 3-kinase in leukocytes". Proc Natl Acad Sci U S A. 94 (4330–4335). doi:10.1073/pnas.94.9.4330.
  3. ^ Okkenhaug, K; Bilancio, A; Farjot, G; Priddle, H; Sancho, S; Peskett, E; Pearce, W; Meek, S.E; Salpekar, A; Waterfield, M.D (2002). "Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice". Science (1031–1034). PMID 10.1126/science.1073560. {{cite journal}}: Check |pmid= value (help)
  4. ^ Ali, K; Soond, D. R; Pineiro, R; Hagemann, T; Pearce, W; Lim, E. L; Bouabe, H; Scudamore, C. L; Hancox, T; Maecker, H (2014). "Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer". Nature (510): 407-411. doi:10.1038/nature13444.
  5. ^ Vanhaesebroeck, B; Roychoudhuri, R; Okkenhaug, K (2019). "PI3K inhibitors in cancer therapy: immune cells takes centre stage". Nat Rev Cancer.
  6. ^ Vanhaesebroeck, B. "30 years of PI3K: an interview with Bart Vanhaesebroeck". Future Oncol: 1–4. doi:10.2217/fon-2024-0215.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Bart_Vanhaesebroeck&oldid=1233336571"